



CoreRx, Inc. announces that its client Bionpharma Inc. has received FDA approval for generic oral suspension Banzel®

CoreRx, Inc. announces that its client Bionpharma Inc. has received FDA approval for generic oral suspension Banzel®(Rufinamide)

CLEARWATER, FL, UNITED STATES, June 3, 2019 /EINPresswire.com/ -- CoreRx, Inc. announces that



This launch represents a significant opportunity to establish CoreRx as a recognized commercial-scale manufacturing facility.”
President and CEO, Todd Daviau

its client Bionpharma Inc. has received FDA approval for a generic version of Banzel® (Rufinamide) Oral Suspension, 40mg/mL. Rufinamide Oral Suspension is a second in a series of products developed and manufactured by CoreRx to be approved for Bionpharma. Rufinamide is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS). Bionpharma plans on launching Rufinamide Suspension upon satisfaction of certain legal and regulatory requirements.

On October 22, 2019, Bionpharma successfully launched

Clobazam Suspension (Onfi®), the first US FDA approved product to be developed and commercially manufactured by CoreRx. Todd R. Daviau, President, and CEO at CoreRx added, “This launch represents a significant opportunity to establish CoreRx as a recognized commercial-scale manufacturing facility. The company’s expanded facilities and capabilities have been tested in both the development as well as commercialization phases.”

Bill Winter, EVP-Sales and Distribution added, “Rufinamide Suspension is a good addition to the growing portfolio of Bionpharma and the company’s endeavor to provide high quality, affordable generics to the US healthcare system.” According to IQVIA™, U.S market annual sales for the 12 months ending December 2018 for Rufinamide Oral Suspension, 40mg/mL is estimated to be approximately \$100 Million

About CoreRx, Inc.

CoreRx, a Contract Development Manufacturing Organization (CDMO) with capabilities to support clinical – niche commercial manufacturing, offering state of the art facilities to support your supply chain needs. Our integrated offerings provide comprehensive services for the development, manufacturing, and testing of solid, liquid and semi-solid dosage forms.

□Keep on top of new developments at CoreRx and throughout the drug development industry by following www.linkedin.com/company/corerx-inc– more detailed information about the company, visit www.corerxpharma.com.

Mark DaFonseca, Chief Business Officer

CoreRx, Inc.

+1 727-259-6950

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.